| Title: |
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature |
| Authors: |
Meijer, Annelot J.M.; Diepstraten, Franciscus A.; Ansari, Marc; Bouffet, Eric; Bleyer, Archie; Fresneau, Brice; Geller, James I.; Huitema, Alwin D.R.; Kogner, Per; Maibach, Rudolf; O Neill, Allison F.; Papadakis, Vassilios; Rajput, Kaukab M.; Veal, Gareth J.; Sullivan, Michael; van den Heuvel-Eibrink, Marry M.; Brock, Penelope R. |
| Contributors: |
Princess Máxima Center for Pediatric Oncology Utrecht, Netherlands; Université de Genève = University of Geneva (UNIGE); Hôpitaux Universitaires de Genève = University Hospital of Geneva Genève (HUG); The Hospital for sick children Toronto (SickKids); Oregon Health and Science University Portland (OHSU); Institut Gustave Roussy (IGR); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Université Paris-Saclay; Cincinnati Children's Hospital Medical Center; Antoni van Leeuwenhoek Hospital; University Medical Center Utrecht (UMCU); Universiteit Utrecht / Utrecht University Utrecht; Karolinska Institutet = Karolinska Institute Stockholm; Dana-Farber Cancer Institute Boston; Great Ormond Street Hospital for Children NHS Foundation Trust London, UK (GOSHC); Newcastle University Newcastle; The Royal Melbourne Hospital; Wilhelmina Children’s Hospital; Princess Máxima Center |
| Source: |
ISSN: 0732-183X. |
| Publisher Information: |
CCSD; American Society of Clinical Oncology |
| Publication Year: |
2024 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; PURPOSE Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Health Regulatory Authority in the United Kingdom. To inform stakeholders regarding the clinical utility of STS, the current review summarizes available literature on the efficacy, pharmacokinetics (PK), and safety of systemic STS to minimize cisplatin-induced hearing loss (CIHL). DESIGN A comprehensive narrative review is presented. RESULTS Thirty-one articles were summarized. Overall, systemic STS effectively reduces CIHL in the preclinical and controlled clinical study settings, in both adults and children with cancer. The extent of CIHL reduction depends on the timing and dosing of STS in relation to cisplatin. Both preclinical and clinical data suggest that systemic STS may affect plasma platinum levels, but studies are inconclusive. Delayed systemic administration of STS, at 6 hours after the cisplatin infusion, does not affect cisplatin-induced inhibition of tumor growth or cellular cytotoxicity in the preclinical setting, nor affect cisplatin efficacy and survival in children with localized disease in the clinical setting. CONCLUSION Systemic administration of STS effectively reduces the development and degree of CIHL in both the preclinical and clinical settings. More studies are needed on the PK of STS and cisplatin drug combinations, the efficacy and safety of STS in patients with disseminated disease, and the ability of STS to prevent further deterioration of pre-established hearing loss. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38648563; PUBMED: 38648563; PUBMEDCENTRAL: PMC11191063 |
| DOI: |
10.1200/JCO.23.02353 |
| Availability: |
https://hal.science/hal-04836027; https://hal.science/hal-04836027v1/document; https://hal.science/hal-04836027v1/file/meijer-et-al-2024-use-of-sodium-thiosulfate-as-an-otoprotectant-in-patients-with-cancer-treated-with-platinum-compounds.pdf; https://doi.org/10.1200/JCO.23.02353 |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.A8CA5C93 |
| Database: |
BASE |